People · Operator
Named in public records as an officer, director or promoter · active 2008–2015 · Other, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pulmonx Corp | — | Other | Series C | $143.8M | $1.1B | 2008 |
| Spinal Modulation Inc | — | Other Health Care | Series C | $76.3M | $1.0B | 2013 |
| SBT Holdings Inc. | — | Other | Series A | $46.9M | $80.2M | 2012 |
| BeneChill, Inc. | — | Other Health Care | Series A | $35.7M | $132.7M | 2009 |
| Sleep Solutions Inc | — | Other Health Care | Series B | $20.0M | $443.1M | 2009 |
| Ekos Corp | — | Other | Series A | $16.8M | $83.2M | 2010 |
| PolyRemedy Inc | — | Other Health Care | Series A | $13.7M | $10.9M | 2014 |
| Neuralieve, Inc. | — | Other Health Care | Series A | $11.4M | $151.0M | 2009 |
| Southern Implants, Inc. | — | Other Health Care | Seed | $5.0M | $49.6M | 2009 |
| INTACT MEDICAL Corp | — | Other Health Care | Seed | $4.8M | $18.6M | 2013 |
| Amnis Corp | — | Biotechnology | Pre-Seed | $894K | $49.3M | 2009 |
Annette Campbell-White at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Annette Campbell-White on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles Liamos | 2 | 4 |
| Graham Blackbeard | 2 | 3 |
| Michael Nealon | 2 | 2 |
| Michael Kehoe | 2 | 2 |
| Carl Gordon | 1 | 24 |
| Michael Greeley | 1 | 15 |
| David Perry | 1 | 11 |
| Denise Barbut | 1 | 9 |
| Adele Oliva | 1 | 9 |
| Noah Knauf | 1 | 9 |
| James Thomas | 1 | 8 |
| Michael Baker | 1 | 8 |
| John K. Bakewell | 1 | 7 |
| Dana G. Mead, Jr. | 1 | 7 |
| Dana Mead | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| Michael Berman | 1 | 7 |
| Mir Imran | 1 | 6 |
| Melissa Daniels | 1 | 6 |
| Sean Carney | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.